Skip to main content

Advertisement

Table 3 Data available for analysis of all treatment comparisons used in intervention studies by population and study characteristics

From: Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses

   n Genotype 1 n (%) Genotype 2 n (%) Genotype 3 n (%)
Prior treatment status Treatment Experienced 47 15 (30.61) 9 (34.62) 23 (45.1)
Treatment Naïve 79 34 (69.39) 17 (65.38) 28 (54.9)
Population All Patients 61 27 (55.1) 13 (50) 21 (41.18)
With Cirrhosis 39 14 (28.57) 8 (30.77) 17 (33.33)
Without Cirrhosis 26 8 (16.33) 5 (19.23) 13 (25.49)
Articles Linas, 2015 20 0 (0) 6 (23.08) 14 (27.45)
Liu, 2014 1 1 (2.04) 0 (0) 0 (0)
Najafzadeh, 2015 3 1 (2.04) 1 (3.85) 1 (1.96)
Saab, 2014 16 16 (32.65) 0 (0) 0 (0)
SanMiguel, 2014 8 2 (4.08) 2 (7.69) 4 (7.84)
Cure, 2015 (Italy) 31 14 (28.57) 8 (30.77) 9 (17.65)
Cure, 2015 (UK) 13 4 (8.16) 4 (15.38) 5 (9.8)
Pfeil, 2015 34 11 (22.45) 5 (19.23) 18 (35.29)
Treatments SOF PEG RBV 12 wk. vs BOC PEG RBV 48 wk 14 14 (28.57) 0 (0) 0 (0)
SOF PEG RBV 12 wk. vs No Tx 7 4 (8.16) 0 (0) 3 (5.88)
SOF PEG RBV 12 wk. vs PEG RBV 24 wk 11 0 (0) 2 (7.69) 9 (17.65)
SOF PEG RBV 12 wk. vs PEG RBV 48 wk 19 13 (26.53) 0 (0) 6 (11.76)
SOF PEG RBV 12 wk. vs TEL PEG RBV 48 wk 11 11 (22.45) 0 (0) 0 (0)
SOF RBV 12 wk. vs No Tx 16 0 (0) 12 (46.15) 4 (7.84)
SOF RBV 12 wk. vs PEG RBV 24 wk 10 0 (0) 8 (30.77) 2 (3.92)
SOF RBV 12 wk. vs PEG RBV 48 wk 4 0 (0) 4 (15.38) 0 (0)
SOF RBV 24 wk. vs No Tx 22 6 (12.24) 0 (0) 16 (31.37)
SOF RBV 24 wk. vs PEG RBV 24 wk 7 0 (0) 0 (0) 7 (13.73)
SOF RBV 24 wk. vs PEG RBV 48 wk 5 1 (2.04) 0 (0) 4 (7.84)
Total   126 49 (38.89) 26 (20.63) 51 (40.48)
  1. Key: BOC = boceprevir; PEG = pegylated interferon; RBV = ribavirin; SOF = sofosbuvir; Tx = treatment; vs = versus; wk. = week
  2. Based on data reported in included intervention models: Cure 2015a [28], Cure 2015b [29], Linas, 2015 [37], Liu 2014 [39], Najafzadeh 2015 [41], San Miguel 2015 [47], Saab 2014 [46]